Description: InnoTherapy, Inc., engages in the development and sale of medical sealant products in South Korea. The company's products include InnoSEAL, an externally applied hemostatic agent; InnoSEAL Plus, an absorbable hemostatic pad; EndoSil, an absorbable hemostatic agent used for the gastrointestinal oozing bleeding; GellySil, a biomaterial and the proprietary material product. It also provides Film-type surgical sealant to complete sealing of anastomosis site; STOP needle, a self-sealing needle for general and ophthalmic use; wound dressing used for chronic wounds, burns, etc.; and Gene therapy, a bio-therapeutics delivery system. The company was founded in 2010 and is headquartered in Seoul, South Korea.
Home Page: www.innotherapy.com
#401, ACE Hitech City 2
Seoul,
07282
South Korea
Phone:
82 2 6959 1338
Officers
| Name | Title |
|---|---|
| Dr. Moonsue Lee | Founder & CEO |
| Mr. Hae-Shin Lee | Founder & CTO |
| Mr. In Keun Moon | CFO, COO & VP |
| Ms. Mi Young Koh Ph.D. | Head of Product Devel. Center |
| Mr. Chang Yeon Kim | Pres of InnoTherapy America, Inc. |
Exchange: KQ
Country: KR
Currency: Korean Won (₩)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 97.2704 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |